| Literature DB >> 30621583 |
Felix N Toka1,2, Kiera Dunaway3, Felicia Smaltz3, Lidia Szulc-Dąbrowska4, Jenny Drnevich5, Matylda Barbara Mielcarska4, Magdalena Bossowska-Nowicka4, Matthias Schweizer6,7.
Abstract
BACKGROUND: Pathogens stimulate immune functions of macrophages. Macrophages are a key sentinel cell regulating the response to pathogenic ligands and orchestrating the direction of the immune response. Our study aimed at investigating the early transcriptomic changes of bovine macrophages (Bomacs) in response to stimulation with CpG DNA or polyI:C, representing bacterial and viral ligands respectively, and performed transcriptomics by RNA sequencing (RNASeq). KEGG, GO and IPA analytical tools were used to reconstruct pathways, networks and to map out molecular and cellular functions of differentially expressed genes (DE) in stimulated cells.Entities:
Keywords: Bomac cells; Bovine macrophage; CpG DNA; PAMPs; Poly(I:C); RNASeq
Mesh:
Substances:
Year: 2019 PMID: 30621583 PMCID: PMC6323673 DOI: 10.1186/s12864-018-5411-5
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Statistics of categorization and abundance of sequence reads generated from 9 cDNA libraries used for differential gene expression analysis
| Sample Name | Assigned reads (millions) | Aligned reads (millions) | Unassigned Ambiguity | Unassigned Multi-mapping (millions) | Unassigned No-feature (millions) |
|---|---|---|---|---|---|
| 1_Control_Expt1 | 30.8 (60.3%) | 37.0 (84.7%) | 31,750 (0.1%) | 14.1 (27.6%) | 6.1 (12%) |
| 2_Control_Expt2 | 36.3 (58.4%) | 43.2 (83.4%) | 37,638 (0.1%) | 18.9 (30.5%) | 6.8 (11%) |
| 3_Control_Expt3 | 33.2 (57.8%) | 39.2 (82.6%) | 34,731 (0.1%) | 18.6 (31.7%) | 6.0 (10.5%) |
| 4_pI_C_Expt1 | 24.5 (57.4%) | 29.1 (83.0%) | 42,708 (0.1%) | 13.5 (31.8%) | 4.6 (10.7%) |
| 5_pI_C_Expt2 | 29.2 (62.3%) | 34.4 (85.8%) | 52,978 (0.1%) | 12.5 (26.7%) | 5.1 (10.9%) |
| 6_pI_C_Expt3 | 23.0 (59.3%) | 27.4 (83.9%) | 41,625 (0.1%) | 11.5 (29.5%) | 4.3 (11.1%) |
| 7_CpG_Expt1 | 27.4 (58.0%) | 32.9 (83.9%) | 27,411 (0.1%) | 14.3 (30.3%) | 5.5 (11.6%) |
| 8_CpG_Expt2 | 24.8 (55.9%) | 29.8 (81.7%) | 25,395 (0.1%) | 14.5 (32.7%) | 5.0 (11.3%) |
| 9_CpG_Expt3 | 27.3 (37.8%) | 32.8 (69.6%) | 27,623 (0.0%) | 39.4 (54.6%) | 5.4 (7.5%) |
Fig. 1Flow cytometric analysis of Bomac cells. Bomac cells were labeled with antibodies against CD14, CD16, CD11b, CD172a, CD44, MHC II, CD40, CD68, CD71, CCR2 and using single color staining. Another set of cells were stimulated with p(I:C) as described in Material and Methods, and then similarly stained for flow cytometry. At least 100,000 events were acquired in FACS Calibur flow cytometer and analyzed in FlowJo software. Results are shown as mean fluorescence intensity (MFI). Six separate stainings for each group of cells were performed. * = p ≤ 0.05
Fig. 2RNASeq Heat map representing 2245 genes differentially expressed in the Bomac cell line responding to stimulation with CpG DNA or poly(I:C). C_1, C_2 and C_3 are control experiments repeated three times. pI:C_4, pI:C_5 and pI:C_6 are Bomac cells stimulated with poly(I:C). CpG DNA_7, CpG DNA_8 and CpG DNA_9 Bomac cells stimulated with CpG DNA. All cells were incubated for 6 h, with each stimulation performed in three separate experiments
Fig. 3Pairwise comparison of differentially expressed genes in Bomac cells stimulated with CpG DNA or poly(I:C). The compared treatment groups are CpG DNA vs control, poly(I:C) vs control, and poly(I:C) vs CpG DNA
Ranking of the top 10 upregulated and downregulated differentially expressed genes in the CpG DNA dataset. Ranking based on fold change
| Gene | ID | Name | Fold change | FDR | |
|---|---|---|---|---|---|
| A | |||||
| TNFSF18 | 768,081 | tumor necrosis factor superfamily member 18 | 5.3 | 6.9 × 10−4 | 2.4 × 10− 2 |
| Slc26a10 | 506,076 | solute carrier family 26 member 10 | 4.3 | 1.2 × 10−3 | 3.5 × 10− 2 |
| NR4A1 | 528,390 | nuclear receptor subfamily 4 group A member 1, transcript variant X3 | 3.1 | 9.7 × 10−5 | 6.2 × 10− 3 |
| IGFLR1 | 617,594 | IGF like family receptor 1 | 3.1 | 6.6 × 10−5 | 4.7 × 10−3 |
| GSDMB | 509,296 | gasdermin B | 2.5 | 6.4 × 10−5 | 4.6 × 10−3 |
| LBH | 616,148 | limb bud and heart development | 2.2 | 6.7 × 10−14 | 4.6 × 10− 10 |
| LY6G5B | 539,236 | lymphocyte antigen 6 complex, locus G5B | 2.2 | 1.4 × 10−3 | 3.9 × 10− 2 |
| MYOZ2 | 540,487 | myozenin 2, transcript variant X1 | 2.7 | 4.01 × 10−5 | 3.5 × 10−3 |
| RRAD | 505,165 | Ras-related associated with diabetes | 2.0 | 5.8 × 10−5 | 4.3 × 10−3 |
| PLAU | 281,983 | plasminogen activator, urokinase receptor | 1.7 | 4.6 × 10−8 | 2.1 × 10−5 |
| B | |||||
| CYP1A1 | 282,870 | cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 1, transcript variant X2 | −2.8 | 4.3 × 10−10 | 6.6 × 10−7 |
| CYP1B1 | 511,470 | cytochrome P450, family 1, subfamily B, polypeptide 1 | −2.4 | 2.0 × 10− 10 | 4.0 × 10−7 |
| ID1 | 497,011 | inhibitor of DNA binding 1, dominant negative helix-loop-helix protein | −2.4 | 3.5 × 10− 16 | 4.9 × 10− 12 |
| GPR35 | 505,056 | G protein-coupled receptor 35, transcript variant X7 | − 2.4 | 2.4 × 10−4 | 1.2 × 10− 2 |
| SLC25A34 | 515,553 | solute carrier family 25 member 34 | − 2.3 | 2.3 × 10−5 | 2.4 × 10− 3 |
| EDN2 | 319,094 | endothelin 2, transcript variant X1 | − 2.1 | 3.4 × 10−8 | 1.7 × 10−5 |
| ATOH8 | 616,225 | atonal bHLH transcription factor 8, transcript variant X1 | −2.1 | 5.1 × 10− 9 | 4.4 × 10− 6 |
| ID3 | 538,690 | inhibitor of DNA binding 3, dominant negative helix-loop-helix protein | −2.0 | 1.2 × 10− 12 | 5.8 × 10− 9 |
| BDKRB1 | 532,119 | bradykinin receptor B1 | −1.9 | 1.1 × 10−4 | 6.7 × 10− 3 |
(A) upregulated, (B) downregulated. Data were analyzed in IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis
Ranking of the top 10 upregulated and downregulated differentially expressed genes in the poly(I:C) dataset. Ranking based on fold change
| Gene | ID | Name | Fold change | FDR | |
|---|---|---|---|---|---|
| A | |||||
| TNFSF10 | 507,215 | tumor necrosis factor superfamily member 10, transcript variant X1 | 3838.1 | 1.5 × 10−17 | 4.1 × 10− 15 |
| IFIT2 | 527,528 | interferon induced protein with tetratricopeptide repeats 2 | 2354.2 | 7.8 × 10− 16 | 1.5 × 10− 13 |
| RSAD2 | 506,415 | radical S-adenosyl methionine domain containing 2 | 2258.9 | 1.9 × 10−28 | 5.2 × 10− 25 |
| IFI44L | 508,347 | interferon induced protein 44 like | 2010.7 | 2.8 × 10−15 | 4.8 × 10− 13 |
| OAS1a | 347,699 | 2′,5′-oligoadenylate synthetase 1, 40/46 kDa | 1591.7 | 9.7 × 10− 23 | 5.3 × 10− 20 |
| IFI44 | 508,348 | interferon induced protein 44, transcript variant X1 | 1254.3 | 1.8 × 10− 13 | 2.6 × 10− 11 |
| ISG15 | 281,871 | ISG15 ubiquitin-like modifier | 1033.6 | 4.9 × 10−30 | 1.6 × 10−26 |
| MX1 | 280,872 | MX dynamin-like GTPase 1, transcript variant X2 | 967.8 | 1.8 × 10−27 | 3.6 × 10− 24 |
| MX2 | 280,873 | MX dynamin-like GTPase 2, transcript variant X1 | 895.4 | 4.0 × 10− 20 | 1.4 × 10−17 |
| OAS2 | 529,660 | 2′-5′-oligoadenylate synthetase 2 | 807.5 | 8.7 × 10− 12 | 9.9 × 10− 10 |
| B | |||||
| CYP1A1 | 282,870 | cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 1, transcript variant X2 | −3.8 | 8.1 × 10− 12 | 9.3 × 10− 10 |
| EXOC3L2 | 539,328 | exocyst complex component 3-like 2 | − 3.7 | 1.2 × 10− 4 | 3.3 × 10− 3 |
| USH1G | 531,104 | Usher syndrome 1G (autosomal recessive) | − 3.3 | 1.3 × 10− 3 | 2.1 × 10− 2 |
| CYP26B1 | 540,868 | cytochrome P450, family 26, subfamily B, polypeptide 1 | − 3.1 | 1.9 × 10− 3 | 2.8 × 10− 2 |
| SMIM17 | 100,849,034 | small integral membrane protein 17, transcript variant X4 | − 2.9 | 1.5 × 10− 3 | 2.3 × 10− 2 |
| DAAM2 | 783,665 | dishevelled associated activator of morphogenesis 2, transcript variant X1 | − 2.8 | 1.1 × 10− 3 | 1.9 × 10− 2 |
| TMEM52 | 617,403 | transmembrane protein 52 | − 2.7 | 3.5 × 10− 3 | 4.4 × 10− 2 |
| CYP1B1 | 511,470 | cytochrome P450, family 1, subfamily B, polypeptide 1 | − 2.6 | 6.8 × 10− 11 | 6.9 × 10− 9 |
| WASF3 | 540,674 | WAS protein family member 3, transcript variant X4 | −2.3 | 2.7 × 10− 3 | 3.1 × 10− 2 |
| ATOH8 | 616,225 | atonal bHLH transcription factor 8, transcript variant X1 | − 2.2 | 9.5 × 10− 10 | 8.2 × 10− 8 |
(A) upregulated, (B) downregulated. Data were analyzed in IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis
Fig. 4Representation of KEGG pathways. Each pathway is a row and each gene set is a column. The red color intensity shows the –log10 (raw p-value), i.e., a value of 6 = 1e-6. As the traditional FDR correction is not appropriate for KEGG or GO testing, we used an extremely low raw p-value to focus on the most highly significant pathways or terms. The numbers in the boxes show the number of genes in the pathway that are significantly up or downregulated, divided by the total number of genes in the pathway. CpG DNAvsCon_up = upregulated genes in the CpG DNA vs control comparison; pI_CvsCon_up = upregulated genes in the poly(I:C) vs control comparison; pI_CvsCpG DNA_up = upregulated genes in the poly(I:C) vs CpG DNA comparison; CpG DNAvsCon_down = downregulated genes in the CpG DNA vs control comparison; pI_CvsCon_down = downregulated genes in the poly(I:C) vs control comparison; pI_CvsCpG DNA_down = downregulated genes in the poly(I:C) vs CpG DNA comparison
Kyoto Encyclopedia of Genes and Genomes pathways generated from CpG DNA or poly(I:C)-stimulated Bomac cells tested at 6 h post stimulation vs control cells
| A | KEGG ID | Pathway | Na | ↑b | ↓c | ||
|---|---|---|---|---|---|---|---|
| a | path:bta04974 | Protein digestion and absorption | 42 | 15 | 1.2 × 10− 20 | 0 | 1 |
| path:bta04512 | ECM-receptor interaction | 55 | 15 | 5.5 × 10−18 | 0 | 1 | |
| path:bta04151 | PI3K-Akt signaling pathway | 233 | 22 | 1.3 × 10−16 | 4 | 4.3 × 10−2 | |
| path:bta04510 | Focal adhesion | 162 | 14 | 5.5 × 10−10 | 4 | 1.8 × 10−2 | |
| path:bta04360 | Axon guidance | 141 | 12 | 3.2 × 10−09 | 4 | 7.4 × 10−3 | |
| b | path:bta04151 | PI3K-Akt signaling pathway | 233 | 22 | 1.3 × 10−16 | 4 | 4.3 × 10−2 |
| path:bta04514 | Cell adhesion molecules (CAMs) | 65 | 7 | 7.2 × 10−07 | 1 | 2.7 × 10−1 | |
| path:bta04210 | Apoptosis | 121 | 9 | 1.4 × 10−06 | 3 | 3.2 × 10−2 | |
| path:bta03320 | PPAR signaling pathway | 44 | 6 | 1.7 × 10−06 | 1 | 2.1 × 10−1 | |
| path:bta04060 | Cytokine-cytokine receptor interaction | 101 | 6 | 5.6 × 10−05 | 3 | 8.7 × 10−3 | |
| B | |||||||
| a | path:bta04621 | NOD-like receptor signaling pathway | 119 | 39 | 3.9 × 10−38 | 2 | 2.4 × 10−1 |
| path:bta05168 | Herpes simplex infection | 146 | 42 | 4.9 × 10−38 | 1 | 6.9 × 10−1 | |
| path:bta05164 | Influenza A | 127 | 35 | 6.0 × 10−31 | 2 | 2.8 × 10−1 | |
| path:bta05162 | Measles | 91 | 26 | 2.8 × 10−23 | 2 | 1.8 × 10−1 | |
| path:bta04622 | RIG-I-like receptor signaling pathway | 48 | 19 | 1.6 × 10−20 | 0 | 1 | |
| b | path:bta04621 | NOD-like receptor signaling pathway | 119 | 39 | 3.9 × 10−38 | 2 | 2.4 × 10−1 |
| path:bta04622 | RIG-I-like receptor signaling pathway | 48 | 19 | 1.6 × 10−20 | 0 | 1 | |
| path:bta04668 | TNF signaling pathway | 84 | 22 | 1.1 × 10− 19 | 3 | 2.8 × 10−2 | |
| path:bta04612 | Antigen processing and presentation | 48 | 18 | 2.4 × 10− 19 | 0 | 1 | |
| path:bta04064 | NF-kappa B signaling pathway | 62 | 17 | 5.4 × 10−16 | 0 | 1 | |
anumber of genes in the pathway; bnumber of genes up-regulated in the pathway; cnumber of genes down-regulated in the pathway
(A) CpG DNA, (B) poly(I:C). (Aa and Ba) Represent top 5 pathways in CpG DNA and poly(I:C) datasets respectively; (Ab and Bb) represent top 5 pathways of immune related genes in the datasets. Gene names in each pathway are shown in the Additional file 3
Fig. 5Gene ontology plotted by PANTHER (http://www.pantherdb.org/) showing biological processes for (a) CpG DNA vs Control upregulated genes; b CpG DNA vs Control downregulated genes; c poly(I:C) vs Control Upregulated genes; d poly(I:C) vs Control downregulated genes; e poly(I:C) vs CpG DNA upregulated genes; f poly(I:C) vs CpG DNA downregulated genes
Fig. 6Charts presenting the Gene Ontology (GO) based classification of differentially expressed genes in Bomac cell line stimulated with CpG DNA or poly(I:C) to cellular components and molecular function processes. a Cellular Components (CC), b Molecular functions (MF). CpG DNAvsCon_up = upregulated genes in the CpG DNA vs control comparison; pI_CvsCon_up = upregulated genes in the poly(I:C) vs control comparison; pI_CvsCpG DNA_up = upregulated genes in the poly(I:C) vs CpG DNA comparison; CpG DNAvsCon_down = downregulated genes in the CpG DNA vs control comparison; pI_CvsCon_down = downregulated genes in the poly(I:C) vs control comparison; pI_CvsCpG DNA_down = downregulated genes in the poly(I:C) vs CpG DNA comparison
Top 5 Canonical pathways generated by Ingenuity Pathway Analysis (IPA) of differentially expressed genes in Bomac cells stimulated with PAMPs (A) CpG DNA vs control, (B) poly(I:C) vs control. https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis
| Canonical Pathway | Ratio | Molecules | ||
|---|---|---|---|---|
| A | Sperm Motility | 3.6 × 10−4 | 4.8 × 10−2 | CNGA, GUY1B3, MST1R, PDE4B, PLA2G12B, PRKCB |
| Nur77 Signaling in T Lymphocytes | 9.9 × 10−4 | 6.8 × 10−2 | CD3G, HDACG, HLA-DMB, NR4A1 | |
| Xenobiotic Metabolism Signaling | 1.5 × 10−3 | 2.8 × 10−2 | CYP1A1, CYP1B1, FTL, HMOXX1, HS3ST2, MAP3K13, MAP3K14 | |
| Calcium-induced T Lymphocyte Apoptosis | 1.5 × 10−3 | 6.1 × 10−2 | CD3G, HLA-DMB, NRA41, PRKCB, | |
| Coagulation System | 2.3 × 10−3 | 8.6 × 10−2 | BDKRB1, PLAU, PLAUR, | |
| B | Interferon Signaling | 2.1 × 10−17 | 4.17 × 10–1 | SOCS1, IFIT3, OAS1, MX1, IRF9, IFI35, PSMB8, TAP1, IRF1, ISG15, IFIT1, STAT2, IFI6, STAT1, IFITM1 |
| Activation of IRF by Cytosolic Pattern Recognition Receptors | 2.3 × 10− 13 | 2.42 × 10− 1 | DHX58, NFKBIE, ZBP1, IRF9, IRF3, ADAR, ISG15, IFIH1, IRF7, NFKBIA, CD40, DDX58, STAT2, IFIT2, STAT1 | |
| Role of Pattern Recognition Receptors in Recognition of Bacteria and Viruses | 4.6 × 10− 10 | 1.24 × 10− 1 | CXCL8, OAS1, C3, OAS2, CCL5, IRF3, RNASEL, TLR2, IFIH1, IRF7, DDX58, TGFB3, PRKCH, IRS2, EIF2AK2, RIPK2, C3AR1 | |
| Death Receptor Signaling | 1.1 × 10−9 | 1.52 × 10−1 | GAS2, DAXX, NFKBIA, PARP10, NFKBIE, ZC3HAV1, TNFSF10, PARP12, PARP3, CASP8, BIRC3, PARP9, CASP7, PARP14 | |
| Antigen Presentation Pathway | 1.9 × 10−8 | 2.37 × 10−1 | B2M, PSMB9, NLRC5, HLA-B, HLA-DMB, CIITA, PSMB8, TAP1, TAP2 |
Top Networks generated from DE genes in Bomac cell line treated with CpG DNA or poly(I:C) for 6 h. (A) CpG DNA, (B) poly(I:C). Data were analyzed in IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis
| Associated Network Functions | Score | |
|---|---|---|
| A | Hematological Disease, Respiratory Disease, Organismal Injury and Abnormalities | 34 |
| Organismal Functions, Hereditary Disorder, Neurological Disease | 32 | |
| Cellular Development, Connective Tissue Development and Function, Tissue Development | 27 | |
| Cellular Assembly and Organization, Cellular Function and Maintenance, Molecular Transport | 27 | |
| Cell Cycle, Embryonic Development, Cancer | 27 | |
| B | Cell-To-Cell Signaling and Interaction, Cellular Movement, Hematological System Development and Function | 33 |
| Cell Death and Survival, Cancer, Hematological Disease | 33 | |
| Protein Synthesis, Lipid Metabolism, Small Molecule Biochemistry | 31 | |
| Cell Death and Survival, Infectious Diseases, Cancer | 29 | |
| Infectious Diseases, Antimicrobial Response, Inflammatory Response | 23 |
Fig. 7The top networks identified in differentially expressed genes in CpG DNA and poly(I:C)-stimulated Bomac cell line after 6 h stimulation, based on Ingenuity Pathway Analysis (IPA, Qiagen) https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis. a CpG DNA-stimulated cells, Hematological Disease, Respiratory Disease, Organismal Injury and Abnormalities network, b poly(I:C)-stimulated cell, Cell-To-Cell Signaling and Interaction, Cellular Movement, Hematological System Development and Function
Common and unique Molecular and Cellular Functions pathways within the top 5 pathways identified in the differentially expressed genes in CpG or pI:C-treated Bomac cells. Data were analyzed in IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis
| Name | #Molecules | ||
|---|---|---|---|
| Common | |||
| pI:C | Cellular Function and Maintenance | 1.5 × 10−4 - 2.6 × 10−16 | 110 |
| CpG | Cellular Function and Maintenance | 7.1 × 10−3 - 2.4 × 10−6 | 62 |
| pI:C | Cell Death and Survival | 2.1 × 10−4 - 4.3 × 10−16 | 149 |
| CpG | Cell Death and Survival | 7.5 × 10−3 - 9.4 × 10−7 | 58 |
| pI:C | Cellular Development | 2.6 × 10−4 - 4.8 × 10− 11 | 134 |
| CpG | Cellular Development | 7.0 × 10−3 - 7.3 × 10−6 | 69 |
| Unique | |||
| CpG | Free Radical Scavenging | 5.8 × 10−4 - 1.4 × 10−8 | 21 |
| CpG | Cell Morphology | 7.3 × 10−3 - 7.3 × 10−6 | 50 |
| pI:C | Cell Signaling | 1.2 × 10−5 - 4.9 × 10−15 | 38 |
| pI:C | Cellular Growth and Proliferation | 2.1 × 10−4 - 4.8 × 10− 11 | 120 |
Fig. 8Functional networks identified in differentially expressed genes in Bomac cells treated with CpG DNA or poly(I:C) upon analysis with Ingenuity Pathway Analysis (IPA). a CpG DNA-stimulated cells, Free Radical Scavenging molecular function network in bovine MΦ, b poly(I:C)-stimulated cells, Cellular Function and Maintenance network in bovine MΦ. https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis
Upstream Regulators identified in CpG DNA and poly(I:C) treated Bomac cell line following 6 h of stimulation. (A) CpG DNA, (B) poly(I:C). Data were analyzed in IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis
| Upstream Regulator | ||
|---|---|---|
| A | TNF | 2.31 × 10−10 |
| ADRB | 9.58 × 10−10 | |
| D-glucose | 9.20 × 10−09 | |
| lipopolysaccharide | 1.71 × 10−08 | |
| dexamethasone | 2.11 × 10− 08 | |
| B | IRF7 | 1.38 × 10−57 |
| poly rI:rC-RNA | 1.08 × 10−46 | |
| IFNL1 | 2.53 × 10− 46 | |
| IFNA2 | 8.27 × 10−44 | |
| Interferon alpha | 3.40 × 10−43 |
Fig. 9Mechanistic networks generated from differentially expressed genes in datasets derived from Bomac cells stimulated with CpG DNA or poly(I:C) for 6 h. a CpG DNA, TNF upstream regulator, b poly(I:C), IRF7 upstream regulator. The mechanistic networks were created with the use of IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis
Top Regulator Effect Networks generated from CpG DNA and poly(I:C)-stimulated Bomac cell line after 6 h of stimulation. (A) CpG DNA, (B) poly(I:C). Data were analyzed in IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis
| Regulators | Diseases & Functions | Consistency Score | |
|---|---|---|---|
| A | Cg,HIF1A,miR-3202 (miRNAs w/seed GGAAGGG) | cell movement of embryonic cell lines | 4.025 |
| BMP6,Ins1,MYC | lymphoproliferative disorder | 3.328 | |
| ERG,RXRA | Growth Failure | 2.121 | |
| miR-4525 (and other miRNAs w/seed GGGGGAU) | Growth Failure | −4.082 | |
| IGF1 | Growth Failure | −5.367 | |
| B | Interferon alpha | Replication of viral replicon | 3.606 |
| Interferon alpha | Viral life cycle | 3.606 | |
| lipopolysaccharide | Replication of viral replicon | 3.464 | |
| PRL | Immune response of cells | 3.357 | |
| IFNA2 | Replication of viral replicon | 3.317 |
Fig. 10Top 5 regulator effect networks from each of the two datasets generated by Ingenuity Pathways. Bomac cells were treated with CpG DNA (a) or poly(I:C) (b) for 6 h. https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis